Patents by Inventor Kyoung-Wan Yoon

Kyoung-Wan Yoon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES THAT SPECIFICALLY BIND TO API5 PROTEIN
    Publication number: 20250019462
    Abstract: The present invention relates to an antibody specifically binding to apoptosis inhibitor 5 (API5) protein and uses thereof. The antibody or antigen-binding fragment thereof that specifically binds to APIS according to the present invention can have excellent anticancer effects, such as inhibiting phosphorylation of ERK in cancer cells and inhibiting cancer growth. In addition, the antibody or antigen-binding fragment thereof exhibits excellent anticancer effects against cancers that are resistant or refractory to anticancer drugs. Accordingly, it is useful for preventing or treating cancers resistant or refractory to anticancer drugs as well as general cancers.
    Type: Application
    Filed: September 27, 2024
    Publication date: January 16, 2025
    Applicant: NEX-I, INC.
    Inventors: Kyoung Wan YOON, Kyungjin BOO, Jeongmin RYOO, Jinyoung SOHN, Junho YEOM, Sujin KIM
  • Pharmaceutical composition for preventing or treating cancer comprising LRIT2 inhibitor as active ingredient
    Patent number: 11787870
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.
    Type: Grant
    Filed: May 15, 2019
    Date of Patent: October 17, 2023
    Assignee: GENOME AND COMPANY
    Inventors: Kyoung Wan Yoon, Youn Kyung Houh, Bu-Nam Jeon, Jinyoung Sohn, Yun Yeon Kim, Suro Lee, Joo-Yeon Chung, Areum Jeong
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING CD300E INHIBITOR AS ACTIVE INGREDIENT
    Publication number: 20210115139
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, containing a CD300E inhibitor as an active ingredient. The CD300E inhibitor according to the present invention can increase the activity of immunocytes so as to be usable as an adjuvant. In addition, the CD300E inhibitor according to the present invention enhances the immunity of an individual, thereby enabling cancer to be effectively prevented or treated.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 22, 2021
    Applicant: GENOME AND COMPANY
    Inventors: Kyoung Wan YOON, Youn Kyung HOUH, Bu-Nam JEON, Jinyoung SOHN, Yun Yeon KIM, Suro LEE, Joo-Yeon CHUNG, Areum JEONG
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING LRIT2 INHIBITOR AS ACTIVE INGREDIENT
    Publication number: 20210009710
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising an LRIT2 inhibitor as an active ingredient. The LRIT2 inhibitor according to the present invention can increase the activity of immune cells, and thus can be used as an immune enhancer. Also, the LRIT2 inhibitor according to the present invention can effectively prevent or treat cancer by enhancing the immunity of an individual.
    Type: Application
    Filed: May 15, 2019
    Publication date: January 14, 2021
    Applicant: GENOME AND COMPANY
    Inventors: Kyoung Wan YOON, Youn Kyung HOUH, Bu-Nam JEON, Jinyoung SOHN, Yun Yeon KIM, Suro LEE, Joo-Yeon CHUNG, Areum JEONG
  • NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING
    Publication number: 20190310261
    Abstract: The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising inhibitors of KIRREL3, CNTN4 and/or CD351. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL3, CNTN4 and/or CD351, and a method of providing information necessary for analysis of cancer prognosis using KIRREL3, CNTN4 and/or CD351.
    Type: Application
    Filed: April 4, 2019
    Publication date: October 10, 2019
    Applicant: GENOME AND COMPANY
    Inventors: Hansoo PARK, Kyoung-Wan YOON, Bu-Nam JEON, Jinyoung SOHN, Yun Yeon KIM, Suro LEE, Youn Kyung HOUH, Joo-Yeon CHUNG, Areum JEONG
  • NOVEL USE OF KIRREL2 AND KIRREL2 INHIBITOR
    Publication number: 20190216840
    Abstract: The present disclosure is based on the discovery that the inhibition of KIRREL2 activity or expression significantly inhibits the development, growth, invasion, and metastasis of cancer. The present disclosure provides a pharmaceutical composition for treating or preventing cancer, comprising KIRREL2 inhibitor. In addition, the present disclosure provides a pharmaceutical composition for immune-enhancing, comprising KIRREL2 inhibitor. Furthermore, the present disclosure provides a method of screening of anti-cancer agent using KIRREL2, and a method of providing information necessary for analysis of cancer prognosis using KIRREL2.
    Type: Application
    Filed: January 11, 2019
    Publication date: July 18, 2019
    Applicant: Genome and Company
    Inventors: Hansoo PARK, Kyoung-Wan Yoon, Jinyoung Sohn, Yun Yeon Kim, Suro Lee, Youn Kyung Houh, Joo-Yeon Chung, Areum Jeong